Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Weight loss options can help protect your kidneys if you have obesity.
-
Other research suggests that high-intensity interval training is the best exercise for lowering blood fats.
-
A large review found that people with prediabetes have a higher risk of developing kidney disease.
Today's news focuses on how managing weight and blood sugar can help protect kidney function. The strongest evidence comes from a review comparing surgery and new drugs for people with obesity. Other studies looked at exercise benefits and the risks of prediabetes.
Evaluating the role of metabolic surgery versus GLP1 agonists in patients living with obesity and chronic kidney disease - a systematic review.
This review looked at 6 studies comparing weight loss surgery and GLP-1 drugs. It found that both options can protect the kidneys in people with obesity and diabetes. This is a high-level summary of existing evidence.
Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
This large review combined data from many clinical trials to look at a common diabetes drug. It found that people taking this drug had higher levels of hemoglobin, a protein in red blood cells. This is a strong finding because it is based on many studies. Higher hemoglobin can help the body carry oxygen better.
Preoperative parathyroid imaging in CKD-related secondary hyperparathyroidism: a systematic review and diagnostic test accuracy network meta-analysis.
This large review compared different scans used to find overactive parathyroid glands. It looked at people with kidney disease who need surgery. It helps doctors pick the best scan to use.
Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE.
This analysis looked at 242 people with type 1 diabetes and kidney disease. They were given the drug finerenone or a placebo. The drug caused a small, temporary drop in kidney filtering rate in the first month. This drop reversed after the treatment ended, suggesting it is a safe side effect.
Dietary sodium intake and kidney tubular protein abundance in urinary extracellular vesicles.
Forty-six healthy adults with normal kidney function tried a very low salt diet, then a high salt diet. The study measured proteins in their urine to see how the kidneys handled salt. It found that salt intake changed the amount of certain kidney proteins. This was a small test, so the results need more study to be sure.
Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial.
A small trial tested a diabetes drug called empagliflozin in people with polycystic kidney disease. The study ran for 12 months and found the drug was safe to use. However, the drug did not slow the growth of the kidneys. It also did not improve how well the kidneys filtered blood.
Evaluation of the preventive effect of intravenous trans-sodium crocetinate followed by oral crocetin on contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angioplasty: A randomized placebo-controlled triple-blind clinical trial.
A trial of 130 people found a plant-based antioxidant helped protect kidneys. The medicine was given before a heart scan. It may lower the risk of kidney damage from the dye.
Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension.
This is a follow-up to a trial of a drug called tolvaptan. The drug is used for a genetic kidney disease. This part of the study lasted two years. It looked at safety and kidney function in children. The study was small, involving only the children who finished the first part of the trial.
Qimei Granules Alleviate Symptoms in Chronic Pancreatitis with Jueyin Disease: A Randomized Double-Blind Placebo-Controlled Trial.
This trial tested a traditional Chinese medicine called Qimei Granules in 102 people with chronic pancreatitis. The treatment lasted six weeks. The study found that the medicine helped reduce symptoms compared to a placebo. It is a small trial, so the results need more confirmation.
Short- and mid-term outcomes of hemodialysis vascular access in pediatric patients.
This study looked at 50 children who needed dialysis. It tracked how well their dialysis access sites worked over time. The study found that some access sites failed or needed repair within a year. This shows a link between access type and complications, not proof of cause. It helps doctors choose the best access for children.
Risk factors associated with rapid progression of chronic kidney disease. A retrospective cohort study.
This study reviewed records of kidney disease patients in a hospital. It looked for factors that might cause kidney function to drop quickly. The study shows a link between certain risk factors and rapid decline, but it is not proof of cause. It helps identify who might be at higher risk.
Trends in metabolic risk factor control and medication use among adults with type 2 diabetes in Taiwan, 2015-2024.
Researchers tracked health records in Taiwan for 10 years to see how well people with type 2 diabetes were managing their health. They found that more people were reaching their blood sugar and cholesterol goals over time. This shows a link between better care and improved health markers, but it does not prove that specific treatments caused the change.
Renin-Angiotensin System (RAS) Inhibitors in High-Risk Patients With Type 2 Diabetes and Cardio-Renal Risk.
This study looked at records for 33,524 adults with type 2 diabetes. It checked how many were taking specific blood pressure drugs that help protect the kidneys. The results show a link between patient status and medication use, but they do not prove cause and effect. This type of review helps doctors see where care might be missing.
Circulating miRNA-21 and Biomarkers of Inflammation, Fibrosis, and Oxidative Stress in Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study.
This study looked at blood markers in people with type 2 diabetes. It found a link between a specific molecule and signs of kidney stress. This is a cross-sectional study, so it shows a link, not proof of cause.
Perioperative Risk Factors and Development of a Clinical Risk Score for Postoperative Acute Kidney Injury in Patients Undergoing Lower Limb Amputation for Vascular Disease
Researchers looked at 101 people who had a leg amputation for blood vessel disease. They found that certain factors, like low blood pressure during surgery, linked to kidney injury. This study shows a link, but it is not proof of cause. It helps doctors spot who is at higher risk.
Are oral and intravenous vitamin C implicated in oxalate-associated renal failure? Exploring the role of pre-existing renal dysfunction.
This review looked at 45 reports of people who had kidney failure after taking vitamin C. It found that most of these people already had weak kidneys. This suggests that vitamin C can be risky for people with existing kidney issues. This is a review of case reports, so it shows a link, not proof of cause.
Paclitaxel-induced scleroderma: A scoping review of reported cases with an illustrative case from our center.
This review looked at published cases of a rare skin condition caused by a chemotherapy drug called paclitaxel. It includes a new case from the authors' center. The study shows a link between the drug and the skin condition, but it is not proof of cause. It helps doctors recognize this side effect.
Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients With Post-Transplantation Diabetes Mellitus - A Cross-Sectional Study.
This study looked at kidney transplant patients in Norway who developed diabetes after their surgery. It checked if a common diabetes drug called an SGLT2 inhibitor helped their bodies process sugar better. The results show a link between using this drug and a healthier metabolic profile. However, this type of study cannot prove that the drug caused the improvement.
Long-term cost-effectiveness of CKD screening in middle-aged adults.
This study used a computer model to estimate the cost of screening for kidney disease in Finland. It looked at whether finding the disease early and treating it with new drugs would save money over time. The model suggests that early screening is a good use of healthcare funds. This is a prediction based on data, not a test on real people.
Compounded GLP-1 Dispensing Patterns and Vitamin B12 Coformulation.
This study looked at prescription data for weight-loss drugs that are mixed in pharmacies. It found that many of these drugs are made with extra ingredients like vitamin B12. It also looked at how often people pay for them out of pocket. This shows how these drugs are being sold and used in the market.